The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Oral Antidiabetic (OAD) Treatment-Global Market Insights and Sales Trends 2024
Synopsis
Diabetic is the condition where the sugar (glucose) level is high in the blood or the production of the insulin is inadequate. Diabetes main type the very first one is Type 1 and the second is Type 2, both the diabetic are most commonly find in the current scenario, apart from this many other diabetics case are also been listed as gestational diabetes and others. Various treatment method are present in the market injection, oral and others. The mostly used method of treatment or managing the diabetes is the oral.
The global Oral Antidiabetic (OAD) Treatment market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Oral Antidiabetic (OAD) Treatment in various end use industries. The expanding demands from the Hospital, Clinics, Diabetics Treatment Centres and Others, are propelling Oral Antidiabetic (OAD) Treatment market. Sulphonylureas, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Biguanides segment is estimated at % CAGR for the next seven-year period.
North America has the 44.3 million population with diabetes in 2015 according to the IDF, same as Europe have 59.8 million in 2015 according to IDF and Asia Pacific has 60% diabetic population as compared with world according to Asian Diabetes Prevention Initiative.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Oral Antidiabetic (OAD) Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Oral Antidiabetic (OAD) Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Oral Antidiabetic (OAD) Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Oral Antidiabetic (OAD) Treatment sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Oral Antidiabetic (OAD) Treatment covered in this report include Pfizer, Eli Lilly, Merck, Sanofi, AstraZeneca, Glenmark, Novartis, Boehringer Ingelheim and Novo Nordisk, etc.
The global Oral Antidiabetic (OAD) Treatment market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
Eli Lilly
Merck
Sanofi
AstraZeneca
Glenmark
Novartis
Boehringer Ingelheim
Novo Nordisk
Mannkind
Global Oral Antidiabetic (OAD) Treatment market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Oral Antidiabetic (OAD) Treatment market, Segment by Type:
Sulphonylureas
Biguanides
Intestinal α-Glucosidase Inhibitors
Others
Global Oral Antidiabetic (OAD) Treatment market, by Application
Hospital
Clinics
Diabetics Treatment Centres
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Oral Antidiabetic (OAD) Treatment companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Diabetic is the condition where the sugar (glucose) level is high in the blood or the production of the insulin is inadequate. Diabetes main type the very first one is Type 1 and the second is Type 2, both the diabetic are most commonly find in the current scenario, apart from this many other diabetics case are also been listed as gestational diabetes and others. Various treatment method are present in the market injection, oral and others. The mostly used method of treatment or managing the diabetes is the oral.
The global Oral Antidiabetic (OAD) Treatment market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Oral Antidiabetic (OAD) Treatment in various end use industries. The expanding demands from the Hospital, Clinics, Diabetics Treatment Centres and Others, are propelling Oral Antidiabetic (OAD) Treatment market. Sulphonylureas, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Biguanides segment is estimated at % CAGR for the next seven-year period.
North America has the 44.3 million population with diabetes in 2015 according to the IDF, same as Europe have 59.8 million in 2015 according to IDF and Asia Pacific has 60% diabetic population as compared with world according to Asian Diabetes Prevention Initiative.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Oral Antidiabetic (OAD) Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Oral Antidiabetic (OAD) Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Oral Antidiabetic (OAD) Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Oral Antidiabetic (OAD) Treatment sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Oral Antidiabetic (OAD) Treatment covered in this report include Pfizer, Eli Lilly, Merck, Sanofi, AstraZeneca, Glenmark, Novartis, Boehringer Ingelheim and Novo Nordisk, etc.
The global Oral Antidiabetic (OAD) Treatment market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
Eli Lilly
Merck
Sanofi
AstraZeneca
Glenmark
Novartis
Boehringer Ingelheim
Novo Nordisk
Mannkind
Global Oral Antidiabetic (OAD) Treatment market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Oral Antidiabetic (OAD) Treatment market, Segment by Type:
Sulphonylureas
Biguanides
Intestinal α-Glucosidase Inhibitors
Others
Global Oral Antidiabetic (OAD) Treatment market, by Application
Hospital
Clinics
Diabetics Treatment Centres
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Oral Antidiabetic (OAD) Treatment companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Oral Antidiabetic (OAD) Treatment
1.1 Oral Antidiabetic (OAD) Treatment Market Overview
1.1.1 Oral Antidiabetic (OAD) Treatment Product Scope
1.1.2 Oral Antidiabetic (OAD) Treatment Market Status and Outlook
1.2 Global Oral Antidiabetic (OAD) Treatment Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Oral Antidiabetic (OAD) Treatment Market Size by Region (2018-2029)
1.4 Global Oral Antidiabetic (OAD) Treatment Historic Market Size by Region (2018-2023)
1.5 Global Oral Antidiabetic (OAD) Treatment Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Oral Antidiabetic (OAD) Treatment Market Size (2018-2029)
1.6.1 North America Oral Antidiabetic (OAD) Treatment Market Size (2018-2029)
1.6.2 Europe Oral Antidiabetic (OAD) Treatment Market Size (2018-2029)
1.6.3 Asia-Pacific Oral Antidiabetic (OAD) Treatment Market Size (2018-2029)
1.6.4 Latin America Oral Antidiabetic (OAD) Treatment Market Size (2018-2029)
1.6.5 Middle East & Africa Oral Antidiabetic (OAD) Treatment Market Size (2018-2029)
2 Oral Antidiabetic (OAD) Treatment Market by Type
2.1 Introduction
2.1.1 Sulphonylureas
2.1.2 Biguanides
2.1.3 Intestinal α-Glucosidase Inhibitors
2.1.4 Others
2.2 Global Oral Antidiabetic (OAD) Treatment Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Oral Antidiabetic (OAD) Treatment Historic Market Size by Type (2018-2023)
2.2.2 Global Oral Antidiabetic (OAD) Treatment Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Oral Antidiabetic (OAD) Treatment Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Oral Antidiabetic (OAD) Treatment Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Oral Antidiabetic (OAD) Treatment Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Oral Antidiabetic (OAD) Treatment Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Oral Antidiabetic (OAD) Treatment Revenue Breakdown by Type (2018-2029)
3 Oral Antidiabetic (OAD) Treatment Market Overview by Application
3.1 Introduction
3.1.1 Hospital
3.1.2 Clinics
3.1.3 Diabetics Treatment Centres
3.1.4 Others
3.2 Global Oral Antidiabetic (OAD) Treatment Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Oral Antidiabetic (OAD) Treatment Historic Market Size by Application (2018-2023)
3.2.2 Global Oral Antidiabetic (OAD) Treatment Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Oral Antidiabetic (OAD) Treatment Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Oral Antidiabetic (OAD) Treatment Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Oral Antidiabetic (OAD) Treatment Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Oral Antidiabetic (OAD) Treatment Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Oral Antidiabetic (OAD) Treatment Revenue Breakdown by Application (2018-2029)
4 Oral Antidiabetic (OAD) Treatment Competition Analysis by Players
4.1 Global Oral Antidiabetic (OAD) Treatment Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Oral Antidiabetic (OAD) Treatment as of 2022)
4.3 Date of Key Players Enter into Oral Antidiabetic (OAD) Treatment Market
4.4 Global Top Players Oral Antidiabetic (OAD) Treatment Headquarters and Area Served
4.5 Key Players Oral Antidiabetic (OAD) Treatment Product Solution and Service
4.6 Competitive Status
4.6.1 Oral Antidiabetic (OAD) Treatment Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Pfizer
5.1.1 Pfizer Profile
5.1.2 Pfizer Main Business
5.1.3 Pfizer Oral Antidiabetic (OAD) Treatment Products, Services and Solutions
5.1.4 Pfizer Oral Antidiabetic (OAD) Treatment Revenue (US$ Million) & (2018-2023)
5.1.5 Pfizer Recent Developments
5.2 Eli Lilly
5.2.1 Eli Lilly Profile
5.2.2 Eli Lilly Main Business
5.2.3 Eli Lilly Oral Antidiabetic (OAD) Treatment Products, Services and Solutions
5.2.4 Eli Lilly Oral Antidiabetic (OAD) Treatment Revenue (US$ Million) & (2018-2023)
5.2.5 Eli Lilly Recent Developments
5.3 Merck
5.3.1 Merck Profile
5.3.2 Merck Main Business
5.3.3 Merck Oral Antidiabetic (OAD) Treatment Products, Services and Solutions
5.3.4 Merck Oral Antidiabetic (OAD) Treatment Revenue (US$ Million) & (2018-2023)
5.3.5 Sanofi Recent Developments
5.4 Sanofi
5.4.1 Sanofi Profile
5.4.2 Sanofi Main Business
5.4.3 Sanofi Oral Antidiabetic (OAD) Treatment Products, Services and Solutions
5.4.4 Sanofi Oral Antidiabetic (OAD) Treatment Revenue (US$ Million) & (2018-2023)
5.4.5 Sanofi Recent Developments
5.5 AstraZeneca
5.5.1 AstraZeneca Profile
5.5.2 AstraZeneca Main Business
5.5.3 AstraZeneca Oral Antidiabetic (OAD) Treatment Products, Services and Solutions
5.5.4 AstraZeneca Oral Antidiabetic (OAD) Treatment Revenue (US$ Million) & (2018-2023)
5.5.5 AstraZeneca Recent Developments
5.6 Glenmark
5.6.1 Glenmark Profile
5.6.2 Glenmark Main Business
5.6.3 Glenmark Oral Antidiabetic (OAD) Treatment Products, Services and Solutions
5.6.4 Glenmark Oral Antidiabetic (OAD) Treatment Revenue (US$ Million) & (2018-2023)
5.6.5 Glenmark Recent Developments
5.7 Novartis
5.7.1 Novartis Profile
5.7.2 Novartis Main Business
5.7.3 Novartis Oral Antidiabetic (OAD) Treatment Products, Services and Solutions
5.7.4 Novartis Oral Antidiabetic (OAD) Treatment Revenue (US$ Million) & (2018-2023)
5.7.5 Novartis Recent Developments
5.8 Boehringer Ingelheim
5.8.1 Boehringer Ingelheim Profile
5.8.2 Boehringer Ingelheim Main Business
5.8.3 Boehringer Ingelheim Oral Antidiabetic (OAD) Treatment Products, Services and Solutions
5.8.4 Boehringer Ingelheim Oral Antidiabetic (OAD) Treatment Revenue (US$ Million) & (2018-2023)
5.8.5 Boehringer Ingelheim Recent Developments
5.9 Novo Nordisk
5.9.1 Novo Nordisk Profile
5.9.2 Novo Nordisk Main Business
5.9.3 Novo Nordisk Oral Antidiabetic (OAD) Treatment Products, Services and Solutions
5.9.4 Novo Nordisk Oral Antidiabetic (OAD) Treatment Revenue (US$ Million) & (2018-2023)
5.9.5 Novo Nordisk Recent Developments
5.10 Mannkind
5.10.1 Mannkind Profile
5.10.2 Mannkind Main Business
5.10.3 Mannkind Oral Antidiabetic (OAD) Treatment Products, Services and Solutions
5.10.4 Mannkind Oral Antidiabetic (OAD) Treatment Revenue (US$ Million) & (2018-2023)
5.10.5 Mannkind Recent Developments
6 North America
6.1 North America Oral Antidiabetic (OAD) Treatment Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Oral Antidiabetic (OAD) Treatment Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Oral Antidiabetic (OAD) Treatment Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Oral Antidiabetic (OAD) Treatment Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Oral Antidiabetic (OAD) Treatment Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Oral Antidiabetic (OAD) Treatment Market Dynamics
11.1 Oral Antidiabetic (OAD) Treatment Industry Trends
11.2 Oral Antidiabetic (OAD) Treatment Market Drivers
11.3 Oral Antidiabetic (OAD) Treatment Market Challenges
11.4 Oral Antidiabetic (OAD) Treatment Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
